Our technology is revolutionizing radiology. We’d love to work with you to help create better outcomes for patients everywhere.
We created the first FDA-cleared device supports concurrent reading, allowing for faster reading with proven, superior, automatic nodule detection.
Our four FDA-cleared applications are designed to improve reading efficiency and accuracy across the hospital enterprise without requiring additional hardware.
Riverain’s deep learning AI technology is FDA cleared, field tested, and clinically proven to provide real results in radiology.
Riverain Technologies advanced AI imaging software is in use by leading healthcare organizations around the world.
Peer reviews, reference accounts, and independent studies confirm that ClearRead technology is positively impacting the field of radiology.
Managing your lung program can seem daunting, whether you’re getting going, growing, or managing workflow. We’ve curated resources for you.
Local business with global reach wants to keep doubling
Riverain Technologies is excited to announce their growth and growing commitment to the Dayton community.
Riverain Technologies – founded in 2004 as Riverain Medical – a pioneer in artificial intelligence (AI) applications for chest imaging. This innovative, cutting edge company continues to grow in Miamisburg and recently upgraded their facilities to accommodate their larger team, their visiting customers and their future aspirations. Fueling this growth is acceleration of interest in their products, including applications designed to improve early lung cancer detection, as well as other applications for detection of disease in chest X-rays and chest CTs.
Riverain CEO Steve Worrell, who joined the company since 2007 as VP of Research took the helm in 2013, shared his excitement for the company’s future. “We are on a mission to save lives through the early detection, diagnosis, and management of lung disease. We know our channel partners and healthcare providers are finding our tools increasingly critical in practice, and we can’t wait to keep bringing more value to chest imaging by doubling down on lung health and cardio-vascular diseases in the chest. As we do that, we intend to keep growing and building both our team and our tools to improve patient outcomes.”
In January, the entire team will celebrate their busy and successful 2021, kick off 2022 and inaugurate the office. “We’ve doubled over last year,” said CFO Thomas Maloney, who also led the team’s new space transition. “We have doubled our space, our team size, our partners, and grown our revenues by more than fifty percent. This team is excited to hit the ground running in 2022 – and intends to launch multiple new products in the coming year.”
|cookielawinfo-checkbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".|
|cookielawinfo-checkbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".|
|cookielawinfo-checkbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".|